ArticleInfectious diseases and therapy2025
Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50-59 Years at Increased Risk of Severe RSV Disease.
David Singer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.